Overview Of: China Approves two Coronavirus Vaccines for Human Trials
China has approved early-stage human tests for two experimental coronavirus vaccines as it battles to contain imported cases and prevent a second wave of COVID-19.
The experimental vaccines are being developed by a Beijing-based unit of Sinovac Biotech and by the Wuhan Institute of Biological Products, an affiliate of state-owned China National Pharmaceutical Group, state news agency Xinhua reported on Tuesday.
Al Jazeera’s Sarah Clarke, reporting from Hong Kong, said China’s National Health Commission also confirmed the trials will go ahead.
In March, Beijing gave the green light to another clinical trial for a coronavirus vaccine candidate developed by the military-backed Academy of Military Medical Sciences and biotech firm CanSino Bio, shortly after US drug developer Moderna said it had begun human tests for their vaccine with the US National Institutes of Health.
“We can confirm now that three particular vaccines are being tested in China, and the National Health Commission has said it will have to clear a number of conditions before they can enable mass production of the vaccines globally,” said Clarke.
As of Tuesday, China reported 82,249 coronavirus cases and 3,341 deaths. There were no fatalities over the past 24 hours.
World's 1st inactivated #coronavirus vaccine has been approved for clinical trial on April 12 in China. (People's Daily) #Covid_19 pic.twitter.com/YIMixHUrGw — China Daily (@ChinaDaily) April 14, 2020